Effect of Atorvastatin on PM10-induced cytokine production by human alveolar macrophages and bronchial epithelial cells

International Journal of Toxicology

Volumn 28, Issue 1, 2009, Pages 17-23

  Van Eeden, Stephan F ^a   Sakamoto, Noriho ^b   Hayashi, Shizu ^b   Mukae, Hiroshi ^b   Vincent, Renaud ^b   Hogg, James C ^b  

^a ST PAUL S HOSPITAL   (Canada)

^b NONE

Author keywords

Alveolar macrophage; Atorvastatin; Bronchial epithelial cell

Indexed keywords

ATORVASTATIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PRAVASTATIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; AIR POLLUTION; AMBIENT AIR; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; LUNG ALVEOLUS MACROPHAGE; LUNG RESECTION; MALE; PARTICULATE MATTER; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; BRONCHUS; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; RESPIRATORY TRACT MUCOSA;

AGED; BRONCHI; CELLS, CULTURED; CYTOKINES; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; PARTICULATE MATTER; PYRROLES; RESPIRATORY MUCOSA; RNA, MESSENGER;

EID: 68049111408     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809333140     Document Type: Article

References (35)

1. Dockery DW, Pope CA III, Xu X, et al. An association between air pollution and mortality in six U.S. cities. N Engl J Med. 1993;329:1753-1759.
2. Pope CA III, Burnett RT, Thurston GD, et al. Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence of general pathophysiological pathways of disease. Circulation. 2004;109:71-77.
3. Becker S, Mundandhara S, Devlin RB, Madden M. Regulation of cytokine production in human alveolar macrophages and airway epithelial cells in response to ambient air pollution particles: further mechanistic studies. Toxicol Appl Pharmacol. 2005;207(2 suppl):269-275.
4. Becker S, Soukup JM, Gallagher JE. Differential particulate air pollution induced oxidant stress in human granulocytes, monocytes and alveolar macrophages. Toxicol In Vitro. 2002;16:209-218.
5. Suwa T, Hogg JC, Quinlan KB, Ohgami A, Vincent R, van Eeden SF. Particulate air pollution induces progression of atherosclerosis. J Am Coll Cardiol. 2002;39:935-942.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
7. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep. 2007;59:483-499.
8. Marz W, Koenig W. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? J Cardiovasc Risk. 2003;10:169-179.
9. Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb. 2004;11:253-264.
10. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest. 2007;132:1764-1771.
11. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med. 2007;176:742-747.
12. Sun XF, Wang LL, Wang JK, et al. Effects of simvastatin on lung injury induced by ischaemia-reperfusion of the hind limbs in rats. J Int Med Res. 2007;35:523-533.
13. Shao H, Shen Y, Liu H, Dong G, Qiang J, Jing H. Simvastatin suppresses lung inflammatory response in a rat cardiopulmonary bypass model. Ann Thorac Surg. 2007;84:2011-2018.
14. Vincent R, Bjarnason SG, Adamson IY, et al. Acute pulmonary toxicity of urban particulate matter and ozone. Am J Pathol. 1997;151:1563-1570.
15. Fujii T, Hayashi S, Hogg JC, et al. Interaction of alveolar macrophages and airway epithelial cells following exposure to particulate matter produces mediators that stimulate the bone marrow. Am J Respir Cell Mol Biol. 2002;27:34-41.
16. Sakamoto N, Hayashi S, Gosselink J, et al. Calcium dependent and independent cytokine synthesis by air pollution particle-exposed human bronchial epithelial cells. Toxicol Appl Pharmacol. 2007;225:134-141.
17. Ishii H, Hayashi S, Hogg JC, et al. Alveolar macrophageepithelial cell interaction following exposure to atmospheric particles induces the release of mediators involved in monocyte mobilization and recruitment. Respir Res. 2005;6:87.
18. Bustin SA. Absolute quantification of mRNA using realtime reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000;25:169-193.
19. Bai N, Khazaei M, van Eeden SF, Laher I. The pharmacology of particulate matter air pollution-induced cardiovascular dysfunction. Pharmacol Ther. 2007;113: 16-29.
20. Tamagawa E, van Eeden SF. Impaired lung function and risk for stroke: role of the systemic inflammation response? Chest. 2006;130:1631-1633.
21. van Eeden SF, Hogg JC. Systemic inflammatory response induced by particulate matter air pollution: the importance of bone-marrow stimulation. J Toxicol Environ Health A. 2002;65:1597-1613.
22. Brook RD. Is air pollution a cause of cardiovascular disease? Updated review and controversies. Rev Environ Health. 2007;22:115-137.
23. Miller KA, Siscovick DS, Sheppard L, et al. Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med. 2007;356:447-458.
24. Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. Circulation. 2001;103:2810-2815.
25. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
26. Seaton A, Soutar A, Crawford V, et al. Particulate air pollution and the blood. Thorax. 1999;54:1027-1032.
27. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J. 2004; 148(1 suppl):S19-S26.
28. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487-48490.
29. Ascer E, Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis. 2004;177:161-166.
30. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007;29:279-283.
31. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61:729-734.
32. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007;85:141-147.
33. Methe H, Kim JO, Kofler S, Nabauer M, Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol. 2005;25:1439-1445.
34. Niessner A, Steiner S, Speidl WS, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis. 2006;189:408-413.
35. Loike JD, Shabtai DY, Neuhut R, et al. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol. 2004;24:2051-2056.